Fintel reports that on March 27, 2026, Barclays upgraded their outlook for Phathom Pharmaceuticals (NasdaqGS:PHAT) from Equal-Weight to Overweight.
Analyst Price Forecast Suggests 116.48% Upside
As of February 25, 2026, the average one-year price target for Phathom Pharmaceuticals is $23.36/share. The forecasts range from a low of $12.12 to a high of $30.45. The average price target represents an increase of 116.48% from its latest reported closing price of $10.79 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Phathom Pharmaceuticals is 460MM, an increase of 162.63%. The projected annual non-GAAP EPS is -4.78.
What is the Fund Sentiment?
There are 190 funds or institutions reporting positions in Phathom Pharmaceuticals. This is an decrease of 70 owner(s) or 26.92% in the last quarter. Average portfolio weight of all funds dedicated to PHAT is 0.31%, an increase of 39.87%. Total shares owned by institutions decreased in the last three months by 8.55% to 63,800K shares. 
The put/call ratio of PHAT is 0.03, indicating a bullish outlook.
What are Other Shareholders Doing?
Frazier Life Sciences Management holds 12,466K shares representing 15.82% ownership of the company. No change in the last quarter.
Medicxi Ventures Management holds 7,465K shares representing 9.47% ownership of the company. No change in the last quarter.
Invesco holds 3,920K shares representing 4.98% ownership of the company. In its prior filing, the firm reported owning 3,865K shares , representing an increase of 1.42%. The firm decreased its portfolio allocation in PHAT by 82.64% over the last quarter.
Carlyle Group holds 3,497K shares representing 4.44% ownership of the company. No change in the last quarter.
Ensign Peak Advisors holds 2,352K shares representing 2.98% ownership of the company. In its prior filing, the firm reported owning 2,503K shares , representing a decrease of 6.43%.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
